This page lists the SEC filings reported by RA Capital Management.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G | 2024-02-12 | RA CAPITAL MANAGEMENT, L.P. | Astria Therapeutics, Inc. | 4,413,150 | 8.1% | EDGAR |
| SC 13G | 2024-02-12 | RA CAPITAL MANAGEMENT, L.P. | Corbus Pharmaceuticals Holdings, Inc. | 430,182 | 4.1% | EDGAR |
| SC 13D/A | 2024-02-06 | RA CAPITAL MANAGEMENT, L.P. | Tyra Biosciences, Inc. | 10,475,489 | 20.0% | EDGAR |
| SC 13G | 2024-02-05 | RA CAPITAL MANAGEMENT, L.P. | Adicet Bio, Inc. | 7,696,949 | 10.0% | EDGAR |
| SC 13G | 2024-02-02 | RA CAPITAL MANAGEMENT, L.P. | Dianthus Therapeutics, Inc. /DE/ | 2,995,023 | 10.0% | EDGAR |
| SC 13G | 2024-01-29 | RA CAPITAL MANAGEMENT, L.P. | Edgewise Therapeutics, Inc. | 8,909,091 | 9.6% | EDGAR |
| SC 13G | 2024-01-19 | RA CAPITAL MANAGEMENT, L.P. | Vaxart, Inc. | 15,384,615 | 9.1% | EDGAR |
| SC 13G | 2024-01-12 | RA CAPITAL MANAGEMENT, L.P. | Longboard Pharmaceuticals, Inc. | 3,073,119 | 8.7% | EDGAR |
| SC 13D/A | 2024-01-11 | RA CAPITAL MANAGEMENT, L.P. | Solid Biosciences Inc. | 4,348,828 | 11.7% | EDGAR |
| SC 13G | 2023-12-29 | RA CAPITAL MANAGEMENT, L.P. | UroGen Pharma Ltd. | 3,083,550 | 10.0% | EDGAR |
| SC 13G | 2023-12-26 | RA CAPITAL MANAGEMENT, L.P. | C4 Therapeutics, Inc. | 4,878,000 | 9.9% | EDGAR |
| SC 13D/A | 2023-12-20 | RA CAPITAL MANAGEMENT, L.P. | Connect Biopharma Holdings Ltd | 3,062,871 | 5.6% | EDGAR |
| SC 13D/A | 2023-12-14 | RA CAPITAL MANAGEMENT, L.P. | Connect Biopharma Holdings Ltd | 5,124,309 | 9.3% | EDGAR |
| SC 13D/A | 2023-12-13 | RA CAPITAL MANAGEMENT, L.P. | 89bio, Inc. | 12,875,855 | 13.6% | EDGAR |
| SC 13D/A | 2023-12-04 | RA CAPITAL MANAGEMENT, L.P. | Connect Biopharma Holdings Ltd | 5,955,011 | 10.8% | EDGAR |
| SC 13G | 2023-11-27 | RA CAPITAL MANAGEMENT, L.P. | Third Harmonic Bio, Inc. | 2,033,056 | 5.0% | EDGAR |
| SC 13D/A | 2023-11-17 | RA CAPITAL MANAGEMENT, L.P. | Eliem Therapeutics, Inc. | 13,176,403 | 47.7% | EDGAR |
| SC 13G/A | 2023-11-14 | RA CAPITAL MANAGEMENT, L.P. | Design Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2023-11-06 | RA CAPITAL MANAGEMENT, L.P. | Harpoon Therapeutics, Inc. | 1,701,570 | 10.0% | EDGAR |
| SC 13G | 2023-10-30 | RA CAPITAL MANAGEMENT, L.P. | MACROGENICS INC | 3,764,871 | 6.1% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.